Iron-Based Binder May Have Advantages Over Sevelamer
Sucroferric oxyhydroxide and sevelemer are similarly effective in lower phosphorus levels in dialysis patients, but the former is associated with less toxicity and lower pill burden.
Phosphate Binders
Phosphorus Control by Dietary Restriction May Lead to Malnutrition
The use of phosphate binders to manage hyperphosphatemia in maintenance hemodialysis patients might allow diets less restricted in protein and calories, according to a study.
Ferric Citrate Approved for Anemia in CKD Patients
Study results show that the phosphate binder was superior to placebo in raising hemoglobin levels in non-dialysis-dependent CKD patients with iron-deficiency anemia.
Phosphate Binder Use Tied With Better Survival
Phosphate binder use is associated with a 25% and 37% decreased risk of death from infection-related causes and all-causes, respectively, compared with non-users.
Distinct Phosphate Targets Feasible, Pilot Study Shows
A randomized controlled pilot study demonstrated the feasibility and safety of performing a large clinical trial that is powered to establish whether phosphate lowering reduces fatal and nonfatal cardiovascular events.
Sevelamer Carbonate Improves Pediatric Hyperphosphatemia
Phase 2 randomized placebo-controlled trial demonstrated the safety and efficacy of sevelamer in lowering serum phosphorus levels in children and adolescents.
Researchers: Iron-based Binders Best for Hyperphosphatemia
Of 7 phosphate binders, iron-based agents were optimal when efficacy and safety are considered.
Iron-based Binder Improves Phosphorus Levels in Dialysis Patients
The proportion of patients with serum phosphorus levels within target range rose from 22% to 65% within 6 months of starting ferric citrate treatment.
Add-on Sevelamer Therapy May Improve Hemodialysis Patient Survival
Use of sevelamer was associated with a 14% decreased risk of death compared with non-use.
Education Can Improve Phosphate Control
Patients receiving educational or behavioral interventions aimed at controlling hyperphosphatemia had an average reduction in phosphate of 0.23 mmol/L more than standard care patients.
- Loading...
Loading...
Next post in Hyperphosphatemia
Loading... 
Loading...